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Abstract
Background: Alzheimer’s disease (AD) is one of the most frequent cause of neurodegenerative disorder in the
elderly. Inflammation has been implicated in brain degenerative processes and peripheral markers of brain AD
related impairment would be useful. Plasma levels of alpha-1-antichymotrypsin (ACT), an acute phase protein and a
secondary component of amyloid plaques, are often increased in AD patients and high blood ACT levels correlate
with progressive cognitive deterioration. During inflammatory responses changes in the micro-heterogeneity of
ACT sugar chains have been described.
Methods: N-Glycanase digestion from Flavobacterium meningosepticum (PNGase F) was performed on both
native and denatured purified ACT condition and resolved to Western blot with the purpose to revealed the ACT
de-glycosylation pattern.
Further characterization of the ACT glycan profile was obtained by a glycoarray; each lectin group in the assay spe-
cifically recognizes one or two glycans/epitopes. Lectin-bound ACT produced a glyco-fingerprint and mayor differ-
ences between AD and controls samples were assessed by a specific algorithms.
Results: Western blot analysis of purified ACT after PNGase F treatment and analysis of sugar composition of ACT
showed significantly difference in “glyco-fingerprints” patterns from controls (CTR) and AD; ACT from AD showing
significantly reduced levels of sialic acid. A difference in terminal GlcNac residues appeared to be related with
progressive cognitive deterioration.
Conclusions: Low content of terminal GlcNac and sialic acid in peripheral ACT in AD patients suggests that a
different pattern of glycosylation might be a marker of brain inflammation. Moreover ACT glycosylation analysis
could be used to predict AD clinical progression and used in clinical trials as surrogate marker of clinical efficacy.
Background
Alzheimer’s disease (AD) is a neurodegenerative disor-
der clinically defined by progressive impairment of
memory and cognitive functions. Brain pathology hall-
marks of AD are extra-cellular amyloid plaques and
intracellular neurofibrillary tangles, along with hyperac-
tive microglia, activated astrocytes, degenerating neurons
and synapsis loss [1].
Alpha-1-antichymotrypsin (ACT) is a secondary com-
ponent of amyloid plaques [2]; it belongs to the super-
family of Serpins (serine protease inhibitors) and is also
known as SERPINA3 [3]. ACT is synthesized in the
liver and in other tissues, including lungs and brain. In
the brain ACT is produced by activated astrocytes
found near brain beta-amyloid (Ab) deposits [4]. It has
been suggested that ACT binds Ab peptide and affects
the rate of amyloid fibril formation in vitro[5,6]. Find-
ings from mouse models of AD have also shown that
ACT over-expression promotes Ab peptide deposition
in the brain of AD animal models [7] and affected their
cognitive performances [8]. More recently, ACT has
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been shown to influence TAU protein phosphorylation
and apoptosis in neuronal cells [9].
Interleukin- a (IL–1a), IL-1ß, IL-6, tumor necrosis
factor a (TNF-a) and other cytokines are up-regulated
and are associated with AD lesions. The inflammatory
cytokines IL-1, IL-6, and TNF-a are produced by both
activated microglia and astrocytes. Moreover, IL-6 and
oncostatin M have been reported to modulate ACT pro-
duction in brain astrocytes [10]. These data have sug-
gested the notion that ACT might be a critical factor
affecting both neurodegenerative process induced by
amyliod deposition and brain inflammatory processes.
The association of gene variations in ACT and other
cytokine genes with the increased risk of AD has further
reinforced the above hypothesis [11].
Whether peripheral levels of ACT may be of practical
use, as AD biomarker or an indicator of the disease clin-
ical progression, remains an open question. In fact, after
the initial reports of increased blood and CSF ACT con-
centrations in AD patients [12-14], several studies mea-
sured ACT concentrations in blood samples drawn from
subjects with AD, with other forms of dementias, and
control subjects. Findings from these studies have pro-
duced conflicting results; some investigations confirming
increased serum ACT levels [12,15,16] others showing
normal ACT blood levels in AD [17,18]. Recent findings
indeed showed that peripheral blood ACT levels were
increased in AD patients or subjects with cognitive
alteration and no dementia and high ACT levels corre-
lated with progressive cognitive deteriorations [19].
These data paralleled other findings showing that ACT
blood levels correlated with cognitive performances in
elderly without dementia [20]. Different techniques for
ACT detection, different criteria for the selection of
controls and AD patients or small numbers of cases and
controls included in the studies may account for contra-
dictory results regarding the association of abnormal
ACT plasma levels with AD. Moreover, alterations in
molecular forms of ACT present in tissues and/or blood
might also account for increased variability of ACT
detection in AD and controls. However, no investigation
has focused upon ACT molecular rearrangement in AD.
ACT plays a role in the modulation of brain amyloid
deposition and immune responses, both processes are
thought to be important contributors to the pathogen-
esis of AD [21]. Inflammatory states are usually asso-
ciated with changes in the glycosylation pattern of acute
phase proteins [22,23]. ACT is a glycoprotein and carbo-
hydrates accounts approximately for 25% of its molecu-
lar weight. The sugar chain composition of ACT was
studied by affinity immune-electrophoresis with Conca-
navalin A [24], by high resolution 1H-NMR spectro-
scopy [25] and, more recently, by mass spectrometry
techniques [26]. ACT contains six N-glycosylation sites
and shows four oligosaccharide side-chains with disialyl
diantennary and trisialyl triantennary type glycan struc-
tures with traces of disialylated triantennary oligosac-
charides. Studies from other biology fields showed that
inflammatory responses causes changes in the micro-
heterogeneity of ACT sugar chains. Such changes were
observed in several disease states, such as prostate can-
cer, myocardial infarction, ovary cancer, septic inflam-
mation, metastatic breast cancer, connective tissue
disease and pulmonary sarcoidosis [24,25,27-29] .
In AD altered glycosilation pattern of presenilin-1, a
molecule forming the catalytic core of the g-secretase
complex and able to generate amyloidogenic peptides
[30] and an abnormal glycosylation of reelin, a glycopro-
tein essential for the correct cyto-architectonic organiza-
tion of the developing CNS, were previously shown [31].
No data on plasma ACT glycosylation patterns in AD
are on record. Here we have shown that glycosylation
pattern of this molecule from the peripheral blood of
AD patients and healthy controls is partially different.
Methods
Patients
The control plasma samples were from the “Conselice
Study of brain aging” [32] and the demented patients
were also from a different Northern Italy clinical longi-
tudinal study, where AD patients were followed up for
two years and their cognitive performances recorded.
Patients and controls were Caucasians and informed
consent from each control and AD relative was
obtained.
Diagnosis of probable AD was performed according to
standard clinical procedure and followed the NINCDS/
ADRDA and DSM-IV-R criteria [33,34]. Cognitive per-
formances were measured according to MMSE. Cogni-
tive decline during the 2 year longitudinal follow up in
AD patients was also assessed by the MMSE scores,
according to the method suggested elsewhere [35].
Purification of ACT from plasma of CTR and AD
Plasma samples from CTR and AD patients with com-
parable ACT levels were chosen. ACT levels in plasma
were measured by using a competitive ELISA assay, as
described elsewhere [19]. Plasma samples from 20 CTR
or 19 AD patients were pooled in 2 distinct experimen-
tal sets (CTR 1 and 2 and AD 1 and 2, respectively). All
experiments were performed using purified ACT
obtained from these plasma sample pools.
Purification of ACT was performed by affinity chro-
matography using Hitrap NHS-activated HP columns
(1 ml) (GE Lifesciences, Milan). 10 mg of sheep anti-
human ACT antibody (AbCam, Cambridge) was coupled
to the column matrix according to the manufacturer’s
instructions.
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Pooled plasma samples (100 μl) containing about 70
μg ACT were diluted to 10 ml with PBS, filtered
through a 0.45 μm filter and applied to the column.
Each sample was left re-circulating for 2h at room tem-
perature using a peristaltic pump at a flow rate of 0.2
ml/min. Thereafter, the column was washed with 10 ml
of PBS and bound ACT was eluted with 0.2 M glycine,
pH 2.8; the purified protein was immediately neutralized
with 5N NaOH and dialyzed against H2O and concen-
trated under reduced pressure.
Assessment of purified ACT concentration by sandwich
ELISA assay
96 well maxisorp plates (Nunc, Milan) were coated with
100 μl of sheep anti-human ACT antibody (AbCam,
Cambridge), diluted 1:1000 in 50 mM Na/CO3 pH 8.5,
incubated overnight at 4°C and washed. If not otherwise
specified, washing of plates was always performed with
4 x 200 μl/well of PBS+0,05% Tween 20x (PBST) and
incubation steps throughout the assay always lasted 2h,
at 37°C, with shaking. After washing, plates were incu-
bated with 100 μl/well of PBST+5% BSA and washed
again.
Thereafter, 100 μl of commercially available ACT
(Sigma, Milan) (dissolved in PBST + 1% BSA), in several
dilutions ranging from 0 to 200 ng/ml to generate a
standard curve, and test samples were added to the
plate wells. After incubation and washing, plates were
incubated with primary antibody (100 μl/well of rabbit
anti-human ACT antibody (Dako, Milan), diluted 1:1000
in PBST+1% BSA) and secondary HRP-conjugated anti-
body (goat anti-rabbit-HRP (Santa Cruz, Heidelberg),
diluted 1:1000 in PBST+1% BSA).
Following the usual PBST washes, an additional wash
with 200 μl of PBS without Tween was performed and
100 μl of peroxidase substrate (ABTS) (Roche, Milan)
diluted in ABTS buffer (Roche, Milan) was added to the
wells.
Absorbance was recorded by an automatic ELISA
reader at 405 nm (Biorad, Milan).
De-glycosylation by N-Glycanase digestion of purified
ACT
N-Glycanase from Flavobacterium meningosepticum
(PNGase F) was used (BioLabs, Milan). De-glycosylation
was performed on both native and denatured purified
ACT.
Reaction in native conditions was performed by incu-
bating 1 µg of purified ACT with 500 U of PNGase F in
50 mM sodium phosphate pH 7.5, 1% NP-40 at 37°C
for 1 and 3 h.
Denaturation of purified ACT was obtained by heat-
ing the protein at 100°C for 10 min in the presence of
0.5% SDS and 40 mM dithiothreitol (DTT). After
denaturation, ACT was reacted with PNGase F, as
described above.
De-glycosylated ACT samples were resolved on a 10%
SDS-polyacrylamide gel, blotted on a PVDF membrane,
visualized by immune reaction with a specific antibody
(rabbit anti-human ACT (Dako, Milan) and revealed by
a Cy5-labelled secondary antibody (GE Lifesciences,
Milan).
Glycan composition analysis of purified ACT
The glycan profile of purified ACT samples was
obtained by using the Qiagen Qproteome™ GlycoArray.
Briefly, 5 μg of purified ACT were absorbed onto the
surface of the GlycoArray slide, following the manufac-
turer’s instructions. Lectin-bound ACT was revealed by
immune reaction using the rabbit anti-human ACT anti-
body (QIAGEN, Dako, Milan) and the Cy5-labelled sec-
ondary antibody (GE Lifescience, Milan). The entire
process was performed in parallel without samples on a
separate control array. At the end of the procedure,
array slides were scanned and analyzed using the Scann
Array 4000 scanner (Packard Biochip Technologies,
Milan). Array image data were analyzed using the Qpro-
teome Glycoarray Analysis Software (QIAGEN), which
calculates the “glyco-fingerprint” of the sample protein
by subtracting the control array signals from the experi-
mental sample array signals. Fingerprint deconvolution
was performed by algorithms using rule-based technol-
ogy calibrated to a wide range of standard proteins.
Each lectin group in the assay specifically recognizes
one or two glycans/epitopes, although a degree of inter-
dependence between these groups is present. This algo-
rithm according to manufacturer calculates relative
abundance of glycan epitopes and provides array-bind-
ing information on the proportion of various features
within a glycoform population.
Results
Clinical, cognitive and epidemiological variables along
with number of subjects, ACT plasma levels, purified
pooled ACT samples, age, gender, cognitive status
assessed by MMSE scores at the time of clinical diagno-
sis and two years later from controls (CTR) and AD are
summarized in Table 1. The AD 1 showed a higher cog-
nitive deterioration during a 2 year follow up than the
AD 2. Plasma samples from 2 different group of control
(CTR 1 and 2) and AD patients (AD 1 and 2) were used
for the purification of ACT and the biochemical analy-
sis. Mean plasma ACT levels between 2 groups of con-
trols and AD patients were comparable, as well as those
of the collected ACT after the purification procedures.
Figure 1 shows Western Blot analysis of purified ACT
from CTR 1 and 2 or AD 1 and 2 treated with PNGase
F. De-glycosylation of native purified ACT form both
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CTR and AD samples resolved into three protein bands
and no qualitative differences were observed between
CTR and AD. On the contrary, when PNGase F treat-
ments was performed on denatured purified ACT, four
bands were detected in both CTR 1 and 2, whereas
ACT from AD samples resolved again into three bands.
Semi quantitative evaluation of fluorescence band inten-
sity from Figure 1 is reported in Table 2. Total fluores-
cence from ACT PAGE electrophoresis and western
blot analysis in band 1 from CTR and AD was compar-
able (CTR 1 = 37977; AD 1 = 44469; CTR 2 = 35449;
AD 2 = 23722). Results regarding total fluorescence and
its percentage in band 1, 2 and 3 (native) and 1, 2, 3
and 4 (denatured) are reported in Table 2. Some differ-
ence was observed in native samples from CTR 2 and
AD 2 after 3 hours of incubation with PNGase F
enzyme. Under mild denaturing treatment band 4 was
never detected in AD 1 and AD 2 and strong difference
in fluorescence intensity in band 1, 2 and 3 after 3
hours of PNGase F digestion were found. Moreover,
fluorescence intensity in band 1, 2 and 3 from AD 1
and AD 2 was quite different from those of CTR 1 and
CTR 2, especially after 3 hour treatment. In fact, in
these condition both total fluorescence intensity and its
percentage, were higher in bands 1 and 2 from AD 1
and AD 2 samples than those detected in CTR 1 and/or
CTR 2.
Further analysis of sugar composition in purified ACT
from CTR 1 and 2 or AD 1 and 2 was performed by
using the Qproteome™ GlycoArray kit. This glyco-array
consisted of 24 lectins covering a large pattern of glycan
specificity. Binding of a glycoprotein to the array results
in a characteristic fingerprint pattern that is highly sen-
sitive to the glycan structure and composition. Glycan
structure semi-quantitatively detectable by the array
include: N-glycans (bi-antennary, tri/tetra antennary,
high mannose, sialic acid, terminal N-acetyl glucosamine
(GlcNac), terminal N-acetyl galactosamine (GalNac) and
bisecting GlcNac and presence or absence of O-glycans.
The fingerprint is interpreted by proprietary knowledge-
based algorithms to produce the glycoanalysis results, a
list of epitopes and their relative abudance.
Fingerprint data, analyzed by the Qproteome™ Gly-
coArray software, produced a detailed profile of ACT
glycosylation status and a glycan epitope prediction pat-
tern by the specific algorithm (Table 3). The Qpro-
teome™ GlycoArray method provides four levels
quantification output for most epitopes: not Detec-
ted=up to 10%, low=11-30%, medium=31-70%, high=71-
100% and a qualitative glycan profile for other epitopes
(detected/not detected). Quantitative difference in puri-
fied ACT lectin reactivity between the experimental sets,
i.e. Purified ACT from AD 1 and 2 showed significantly
reduced levels of sialic acid when compared to those
from CTR 1 and 2. Moreover, a difference in terminal
GlcNac residues was found between AD 1 and AD 2
groups. It is interesting to note that AD 1 showed a fas-
ter cognitive deterioration than AD 2 in a 2 years follow
up. In fact, as shown in Table 1, AD 1 patients loosed 5
points in the MMSE score and AD 2 patients only 1
point.
Discussion
Glycosylation is a versatile biochemical mechanism and
one of the most abundant post-translational modifica-
tion of protein; however, glycosylation of proteins is
not a template driven process, is difficult to predict
[36] and affects molecule stability, resistance to proteo-
lysis, solubility and molecule functional activity. There-
fore, this protein modification may play a role in
affecting biological activity of molecules with a special
role in the metabolic events related to neuro-degenera-
tion and AD.
ACT is a glycoprotein and carbohydrate content reach
24% of molecular weight. This acute phase proteins is
mainly synthesized by the liver, however, other tissues
are able to produce and release this molecule. In fact,
astrocytes synthesized and release ACT and increased
levels of this protein have been found in the brain, CSF
and blood from AD patients [15,19,37]. ACT levels in
Table 1 Epidemiological and clinical features from investigated subjects
CTR 1 CTR 2 AD 1 AD 2
N° of samples 10 10 9 10
ACT mean (µg/ml) 763 789 695 876
ACT purify (µg/ml) 26 38 27 32
Age 73 75 80 77
Gender 9 F - 1 M 4 F – 6 M 7 F - 2 M 7 F - 3 M
Evolution 4 S- 1 I - 5 NA 2 S- 5 I- 3 NA 2 F – 6 I – 1 S 1 F – 5 I – 4 S
MMSE time 0 28 28 19 19
MMSE after 2 year follow up 27 26 13 18
Number of subjects, ACT plasma levels, purified ACT of subjects’s pool, age, gender, group of cognitively state, MMSE scores at the beginning of the study and
two years later are summarized in this table.
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Figure 1 Western blot analysis of ACT after PNGase F digestion. Panel A. Lane 1, CTR 1 incubated 3 hours without PNGaseF; lane 2, CTR 1
in condition Native incubated for 1 h; lane 3, CTR 1 Native incubated for 3 h; lane 4, CTR 1 Denatured incubated for 1 h; lane 5, CTR 1
Denatured incubated for 3 h; lane 6, AD 1 incubated 3 hours without PNGaseF; lane 7, AD 1 Native incubated for 1 h; lane 8, AD 1 Native
incubated for 3 h; lane 9, AD 1 Denatured incubated for 1 h; lane 10 AD1 Denatured incubated for 3 h. Panel B refers to CTR 2 and AD 2 with
the same treatment. MW= molecular weight.
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the blood markedly increases after tissue damages or
infections [38]. We already postulated that a proportion
of plasma ACT in AD might derive from the brain as a
by-product of neurodegenerative processes and inflam-
mation in the central nervous system [39]. As for other
glycoproteins, micro-heterogeneity of ACT may be
ascribed to differences in carbohydrate structure and
indeed different patterns of ACT micro-heterogeneity
has been shown in different diseases [40,41].
To obtain usable level of purified ACT, samples from
AD or control were pooled; plasma samples showing
comparable levels of this serpin, as assessed by competi-
tive ELISA, i.e. moderately high ACT levels, were cho-
sen. This step is relevant, since plasma levels of ACT
and other serpins increase in different pathological con-
ditions; however, in this investigation both patients con-
trols were free from cancer, infections and inflammatory
diseases.
Here we showed that after partial denaturation, puri-
fied ACT from AD plasma samples were less sensitive
to enzymatic digestion by N-glycanase than ACT from
plasma samples of healthy donors. This first observation
suggested a different glycosylation pattern in ACT form
AD patients, since denaturation was shown to increase
deglycosylation by glycanase [25]. Different deglycosyla-
tion patterns of denatured ACT between AD and CTR
may be ascribed to differentially presence of fucose resi-
dues linked a(1-3) to ASN bound N-acetylglucosamine
that resistant to PNGase F action.
Purified ACT was then analysed by a lectin array spe-
cifically developed for investigating protein glycan con-
tent and composition [42]. This analysis resulted in a
partially different pattern of glycan profiles between
ACT from AD and controls; sialic acid content being
different between AD and CTR.
This alteration may have several explanations. For
instance, a proportion of circulating ACT in AD plasma
may derive from other tissues than liver, possibly the
Table 2 Fluorescence intensity analysis after PNGase F treatment
PANEL A CTR 1 AD 1
Band Native 1 1 h Native 3 3 h Denatured 1 h Denatured 3 h Native 1 1 h Native 3 3 h Denatured 1 h Denatured
3 h
1 12271
(41.2%)
11658
(38.6%)
8608
(57%)
978
(5.5%)
20528
(40.5%)
16066
(37.4%)
10821
(30.5%)
10480
(25.3%)
2 5297
(17.8%)
5272
(17.4%)
4313
(28%)
9264
(52.6%)
10135
(20%)
5651
(13.1%)
12959
(36.6%)
15418
(37.1%)
3 12229
(41%)
13257
(44%)
2240
(15%)
4689
(26.6%)
19972
(39.5%)
21315
(49.5%)
11668
(32.9%)
15594
(37.6%)
4 2702
(15.3%)
PANEL B CTR 2 AD 2
Band Native 1 1 h Native 3 3 h Denatured 1 h Denatured 3 h Native 1 1 h Native 3 3 h Denatured 1 h Denatured
3 h
1 18537
(46.7%)
12721
(44.9%)
6925
(25.1%)
5234
(15.7%)
10371
(44.4%)
10937
(37.2%)
6649
(37.1%)
5579
(36.7%)
2 6293
(15.9%)
2825
(10%)
11136
(40.4%)
14381
(43.3%)
2916
(12.5%)
4048
(13.8%)
5527
(30.8%)
3913
(25.8%)
3 14817
(37.4%)
12804
(45.1%)
6094
(22.1%)
10005
(30.1%)
10083
(43.1%)
14385
(49%)
5759
(32.1%)
5706
(37.5%)
4 3428
(12.4%)
3632
(10.9%)
Band fluorescence intensity after PNGase F treatment (see Western Blot bands in figure 1, panels A and B).
Table 3 Glycan epitope pattern of Cy5 labeled ACT
Glycan epitope CTR 1 AD 1 CTR 2 AD 2
N-linked:
Bi Antennary Not
Detected
Not
Detected
Not
Detected
Not
Detected
Tri/Tetra
Antennary
High High High High
High Mannose Not
Detected
Not
Detected
Not
Detected
Not
Detected
Sialic Acid High Medium High Medium
Terminal GlcNAc Low Low Low Not
Detected
Terminal GalNAc Not
Detected
Not
Detected
Not
Detected
Not
Detected
Bisecting GlcNAc Not
Detected
Not
Detected
Not
Detected
Not
Detected
O-Glycans Not
Detected
Not
Detected
Not
Detected
Not
Detected
Glycan profile produced for ACT using the Qproteome Glycoarray method.
ND=not detected (up to 10%); Low=11-30%; Medium=31-70%; High=71-100%.
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brain and this molecules might show a different glycosy-
lation signature.
On the other hand, we can not exclude another inter-
pretation suggesting that altered ACT glycan profile
from AD samples may reflect a generalized impairment
of glycosylation processes involving other glycoproteins.
In fact, it has previously shown that reelin, a glycopro-
tein essential for the correct cyto-architecture organisa-
tion of developing brain and involved in signalling
pathways linked to neuro-degeneration in several
human diseases, were increased in the brain from neu-
rological disorders and showed a different glycosylation
patterns in plasma from AD [31]. Moreover, acetylcho-
line esterase from AD samples analyzed by lectin bind-
ing activity showed different binding properties when
compare with those from controls [43].
Also our data showed a slight but significant differ-
ence in the two AD sets. AD 1 showing higher fluores-
cence intensity in terminal GlcNac and sialic acid than
AD 2. Patients belonging to the AD 1 group showed a
faster cognitive deterioration rate in a 2 year follow up.
Overall our data suggest altered sialic acid content in
ACT from AD samples and the potential presence of
focuse residues in the denatured ACT from CTR than
AD samples.
Conclusion
Altered glycosylation pattern in purified ACT from the
peripheral blood of AD maight be ascribed to an
increased inflammation of the brain or an altered glyca-
tion process of ACT along with several other brain
proteins in AD.
Our findings suggest that low content of terminal
GlcNac glycans and sialic acid in peripheral ACT might
be a marker of diseases progression and it might be
used in clinical trials as surrogate marker of clinical
efficacy.
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